Teva Pharmaceutical Industries (Teva or 'the company') is a provider of generic pharmaceuticals. The company also offers proprietary branded pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients (APIs). The company has direct operations in approximately 60 countries, as well as 40 finished dosage pharmaceutical manufacturing sites with two additional sites currently under construction in 25 countries, 20 API sites and more than 20 pharmaceutical R&D centers. Teva operates through two business segments: generic medicines and specialty medicines. In addition to these two segments, the company generates revenues from other activities. The generic medicines segment of the company develops, manufactures, sells and distributes generic or branded generic medicines as well as APIs. Generic products of Teva include chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The specialty medicines segment of Teva is engaged in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system (CNS), oncology and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. Specialty products of Teva include several core therapeutic areas of CNS (with an emphasis on multiple sclerosis, neurodegenerative disorders, and pain care) and respiratory medicines (with a focus on asthma and chronic obstructive pulmonary disease. as well as products in oncology, women's health and selected other areas. The company's specialty business also includes its emerging new therapeutic entities activity. New therapeutic entities are known molecules that are formulated, delivered or used in a novel way to address specific patient needs. Teva's other activities include the over the counter (OTC) medicines business, which is conducted through PGT Healthcare, Teva's joint venture with The Procter & Gamble Company (P&G); distribution activity mainly in Israel and Hungary; and sales of medical devices.
Scope of the Report
-- About the Company - Historical Details, Current Ownership Structure and basic overview of Teva Pharmaceutical Industries Limited in terms of revenue, net income, and operating income.
-- Financials - Details about Teva Pharmaceutical Industries Limited listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
-- Company SWOT Analysis - Outlines Teva Pharmaceutical Industries Limited’s strengths, weaknesses, and opportunities and threats facing the company.
-- Recent Developments - Showcases Teva Pharmaceutical Industries Limited’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
-- Strategic Evaluation - Provides an overview of Teva Pharmaceutical Industries Limited’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
-- What domain does Teva Pharmaceutical Industries Limited operate and what are key points about it?
-- What is the product / service portfolio of Teva Pharmaceutical Industries Limited?
-- How has Teva Pharmaceutical Industries Limited performed financially from the 2013?
-- How does Teva Pharmaceutical Industries Limited rank among its peers in terms of revenue and market share?
-- What are Teva Pharmaceutical Industries Limited strengths and weaknesses and what opportunities and threats does it face?
-- What are Teva Pharmaceutical Industries Limited’s main growth strategies and how successful has the company been at implementing them?
-- What is the in-house technical capability of Teva Pharmaceutical Industries Limited? Where does it procure / outsource it?
Reasons to buy
-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
-- 12 hour delivery time fulfilling your urgent requests as per your requirement
-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
-- 7.1.1 Industry Snapshot
-- 7.1.2 IT Spend
-- 7.1.3 Key Information Technology Trends
-- 7.2.1 IT Overview
-- 7.2.2 Key IT Technologies
-- 7.2.3 Recent IT Initiatives
-- 7.2.4 IT Outsourcing Engagements
-- 7.2.5 Key IT Management
-- 7.2.6 CIO/CTO Profile
-- About Us
-- Contact Us
Fig.1: Company Snapshot
Fig.2: Locations Listing on Map
Table.1: Ownership Structure
Table.2: List of Competitors
Table.3: Annual Statements
Table.4: Key Financial Highlights
Table.5: Region-wise Breakdown
Table.6: Product/Services Overview
Table.7: Mergers & Acquisitions
Table.8: Partnerships, Collaborations & Joint Ventures
Table.9: New Product Launches
Table.10: Business Expansion / Divestment
Table 11: IT Budgets
Table 12: Key IT Management (CIO / CTO)
Table 13: IT Deals undertaken in the past years